KPTI News and Press, Karyopharm Therapeutics Inc. From 10/28/19

NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's management team will host a conference ...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

New York, New York--(Newsfile Corp. - September 20, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff i...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it is entering a royalty agreement with HealthCare Royalty Partners, boosting KPTI stock. Karyopharm, a Massachusettes-based pharmaceutical firm, will receive an initial $75 million USD by the end of this month for HCR, ...

Karyopharm Therapeutics (NASDAQ: KPTI ) inks an agreement with HealthCare Royalty Partners (HCR) to sell XPOVIO (selinexor) royalties for $75M upfront plus another $75M contingent on the the achievement of certain regulatory and commercial milestones. More news on: Karyopharm Therap...

Karyopharm Therapeutics (NASDAQ: KPTI ) has entered into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150M to support the development and commercialization of XPOVIO (selinexor), an oral selective inhibitor of nuclear export compound, for the treatme...

NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing development and c...

NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17 th International Myeloma ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ) slips  1%  premarket on heels of  Phase 2b data on XPOVIO (selinexor), combined with low-dose dexamethasone, in patients with heavily pretreated triple class refractory multiple myeloma (MM). The results were just published in the onlin...